- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2012
- Public Summary Document (PSD) March 2012 PBAC Meeting - PDF
Pazopanib – March 2012
Pazopanib, tablet, 200 mg and 400 mg (as hydrochloride), Votrient® - March 2012
Last updated
8 November 2023